mRNA Expression in Papillary and Anaplastic Thyroid Carcinoma: Molecular Anatomy of a Killing Switch

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Hébrant, Aline ^a   Dom, Geneviève ^a   Dewaele, Michael ^b   Andry, Guy ^c   Trésallet, Christophe ^d   Leteurtre, Emmanuelle ^e,f   Dumont, Jacques E ^a   Maenhaut, Carine ^a,g  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIV LILLE   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; MESSENGER RNA;

ANAPLASTIC THYROID CANCER; ARTICLE; CALCIFICATION; CANCER CELL; CANCER INVASION; CANCER RESISTANCE; CELL DEDIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE SWITCHING; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PHENOTYPE; QUALITATIVE ANALYSIS; TUMOR GROWTH;

CARCINOMA; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 84868128308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037807     Document Type: Article

References (70)

1. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr.Relat Cancer, 16, 17-44.
2. Ain KB (1999) Anaplastic thyroid carcinoma: a therapeutic challenge. Semin.Surg.Oncol, 16, 64-69.
3. Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann.Surg.Oncol, 13, 453-464.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 109-142.
5. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, et al. (2008) Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene, 27, 1554-1561.
6. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, et al. (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res, 67, 10148-10158.
7. van Staveren WC, Weiss Solis D, Delys L, Venet D, Cappello M, et al. (2006) Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc.Natl.Acad.Sci.U.S.A, 103, 413-418.
8. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3.
9. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, et al. (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol, 22, 3531-3539.
10. Delys L, Detours V, Franc B, Thomas G, Bogdanova T, et al. (2007) Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene, 26, 7894-7903.
11. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, et al. (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc.Natl.Acad.Sci.U.S.A, 98, 15044-15049.
12. Jarzab B, Gubala E, Lange D (2005) [DNA microarrays and papillary thyroid carcinoma gene expression profile]. Endokrynol.Pol., 56, 293-301.
13. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol., 4, 3.
14. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol., 4, R70.
15. Borrello MG, Degl'Innocenti D, Pierotti MA (2008) Inflammation and cancer: the oncogene-driven connection. Cancer Lett, 267, 262-270.
16. Salerno P, Garcia-Rostan G, Piccinin S, Bencivenga TC, Di Maro G, et al. (2011) TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. J Clin Endocrinol Metab, 96, E772-E781.
17. Vasko V, Espinosa AV, Scouten W, He H, Auer H, et al. (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A, 104, 2803-2808.
18. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, et al. (2011) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest, 121, 1064-1074.
19. Mizukami Y, Michigishi T, Nonomura A, Noguchi M, Nakamura H (1995) Thyroid carcinoma: clinical, pathologic correlations. Crit Rev Oncol Hematol., 18, 67-102.
20. Barker HE, Chang J, Cox TR, Lang G, Bird D, et al. (2011) LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution. Cancer Res, 71, 1561-1572.
21. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, et al. (2009) Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer, 125, 894-901.
22. Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp.Metastasis, 10, 145-155.
23. Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, et al. (2010) Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol.
24. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, et al. (2011) Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene, 30, 1302-1317.
25. Xiao L, Chen Y, Ji M, Dong J (2011) KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem., 286, 7788-7796.
26. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, et al. (1991) Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol.Cell Endocrinol, 82, R7-12.
27. El Housni H, Lecocq R, Christophe D (1997) Production of dog calcyphosine in bacteria and lack of phosphorylation by the catalytic subunit of protein kinase A in vitro. Mol.Cell Endocrinol, 135, 93-97.
28. Costa MJ, Senou M, Van Rode F, Ruf J, Capello M, et al. (2007) Reciprocal negative regulation between thyrotropin/3',5'-cyclic adenosine monophosphate-mediated proliferation and caveolin-1 expression in human and murine thyrocytes. Mol.Endocrinol., 21, 921-932.
29. Frohlich H, Boini KM, Seebohm G, Strutz-Seebohm N, Ureche ON, et al. (2011) Hypothyroidism of gene-targeted mice lacking Kcnq1. Pflugers Arch., 461, 45-52.
30. Song Y, Ruf J, Lothaire P, Dequanter D, Andry G, et al. (2010) Association of duoxes with thyroid peroxidase and its regulation in thyrocytes. J Clin Endocrinol Metab, 95, 375-382.
31. Deleu S, Savonet V, Behrends J, Dumont JE, Maenhaut C (2002) Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas. Exp.Cell Res., 279, 62-70.
32. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, et al. (2009) The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle, 8, 1367-1372.
33. Doll A, Gonzalez M, Abal M, Llaurado M, Rigau M, et al. (2009) An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int J Cancer, 125, 257-263.
34. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, et al. (2006) Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev, 25, 589-600.
35. Brahimi-Horn MC, Bellot G, Pouyssegur J (2011) Hypoxia and energetic tumour metabolism. Curr.Opin.Genet Dev., 21, 67-72.
36. Lawler J. (2000) The functions of thrombospondin-1 and-2. Curr.Opin.Cell Biol, 12, 634-640.
37. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, et al. (2002) IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood, 100, 1728-1733.
38. Nagaya N, Mori H, Murakami S, Kangawa K, Kitamura S (2005) Adrenomedullin: angiogenesis and gene therapy. Am.J Physiol Regul.Integr.Comp Physiol, 288, R1432-R1437.
39. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG (2005) The role of adrenomedullin in angiogenesis. Peptides, 26, 1670-1675.
40. Li Y, Cozzi PJ (2007) Targeting uPA/uPAR in prostate cancer. Cancer Treat.Rev, 33, 521-527.
41. Maenhaut C, Dumont JE, Roger PP, van Staveren WC (2010) Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis, 31, 149-158.
42. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, et al. (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol.
43. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, et al. (2011) Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp.Biol Med (Maywood.), 236, 537-545.
44. Lam KY, Lo CY, Chan KW, Wan KY (2000) Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann.Surg., 231, 329-338.
45. Hebrant A, van Staveren WC, Delys L, Solis DW, Bogdanova T, et al. (2007) Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp.Cell Res, 313, 3276-3284.
46. Carcangiu ML, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma. A study of 70 cases. Am.J Clin Pathol., 83, 135-158.
47. Nel CJ, van Heerden JA, Goellner JR, Gharib H, McConahey WM, et al. (1985) Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc, 60, 51-58.
48. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer, 103, 2261-2268.
49. Riesco-Eizaguirre G, Santisteban P (2007) New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr.Relat Cancer, 14, 957-977.
50. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, et al. (2003) Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab, 88, 4440-4445.
51. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, et al. (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 87, 3947-3952.
52. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 88, 5399-5404.
53. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, et al. (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res, 4, 287-294.
54. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid, 21, 125-134.
55. Gopal PP, Montone KT, Baloch Z, Tuluc M, LiVolsi V (2011) The variable presentations of anaplastic spindle cell squamous carcinoma associated with tall cell variant of papillary thyroid carcinoma. Thyroid, 21, 493-499.
56. Malaguarnera R, Vella V, Vigneri R, Frasca F (2007) p53 family proteins in thyroid cancer. Endocr.Relat Cancer, 14, 43-60.
57. Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 330, 1340-1344.
58. Mason EF, Zhao Y, Goraksha-Hicks P, Coloff JL, Gannon H, et al. (2010) Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res, 70, 8066-8076.
59. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest, 91, 179-184.
60. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, et al. (1997) p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene, 14, 729-740.
61. Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P, et al. (2008) Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol.Biol Cell, 19, 4814-4825.
62. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, et al. (1999) Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res, 59, 1811-1815.
63. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res, 69, 4885-4893.
64. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, et al. (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res, 64, 3780-3789.
65. Murugan AK, Xing M (2011) Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene. Cancer Res, 71, 4403-4411.
66. De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr.Opin.Genet Dev., 21, 73-79.
67. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, et al. (2007) Anaplastic thyroid carcinoma: an overview. Curr.Oncol Rep., 9, 152-158.
68. Alison MR, Lim SM, Nicholson LJ (2011) Cancer stem cells: problems for therapy? J Pathol., 223, 147-161.
69. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu.Rev Med, 58, 267-284.
70. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C (2011) Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene.